Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human gut mycobiome

ABSTRACT: Human intestinal mycobiome in nonalcoholic fatty liver disease Targeted loci

PROVIDER: PRJNA698272 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13762700_1.fastq.gz	Fastqsanger.gz
	SRR13762700_2.fastq.gz	Fastqsanger.gz
	SRR13762701_1.fastq.gz	Fastqsanger.gz
	SRR13762701_2.fastq.gz	Fastqsanger.gz
	SRR13762702_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 188

Similar Datasets

human gut mycobiome

Project description:Human intestinal mycobiome in alcoholic liver disease Targeted loci

| PRJNA517994 | ENA

human gut mycobiome

Project description:Human intestinal mycobiome in alcohol use disorder Targeted loci

| PRJNA703732 | ENA

HTN gut mycobiome

Project description:HTN gut mycobiome Targeted loci environmental

| PRJNA895827 | ENA

human gut metagenome

Project description:Human gut mycobiome in alcoholic liver disease Targeted loci

| PRJNA317653 | ENA

Next Generation Sequencing Analysis of Pparafl/fl and PparaΔIE intestinal transcriptomes

Project description:Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic diseases globally and nonalcoholic steatohepatitis is its progressive stage with limited therapeutic options. Here a role for intestinal peroxisome proliferator-activated receptor α (PPARα)-fatty acid binding protein 1 (FABP1) in obesity-associated metabolic syndrome, fatty liver and nonalcoholic steatohepatitis via modulating dietary fat absorption was uncovered. Intestinal PPARα is highly activated accompanied by marked upregulation of FABP1 by high-fat diet (HFD) in mice and obese humans. Intestine-specific PPARα or FABP1 disruption in mice decreases HFD-induced obesity, fatty liver and nonalcoholic steatohepatitis and intestinal PPARα disruption fails to further decrease obesity and NASH. Chemical PPARα antagonism improves metabolic disorders depending on the presence of intestinal PPARα or FABP1. Translationally, GW6471 decreases human PPARα-driven intestinal fatty acid uptake and therapeutically improves obesity in PPARA-humanized, but not Ppara-null, mice. These results suggest that intestinal PPARα-FABP1 axis could be a therapeutic target for NASH.

2022-09-01 | GSE190140 | GEO

stool mycobiome in GDM patients

Project description:stool mycobiome in GDM patients Targeted loci

| PRJNA813503 | ENA

Project description:Dark tea improves nonalcoholic fatty liver disease through intestinal flora

| PRJNA858285 | ENA

gut metagenome

Project description:Murine and Humanized intestinal microbiome in alcoholic liver disease Targeted loci

| PRJNA525701 | ENA

Lack of GPR180 ameliorates hepatic lipid depot via downregulation of mTORC1 signaling

Project description:Our previous genome-wide association study to explore genetic loci associated with lean nonalcoholic fatty liver disease (NAFLD) in Japan suggested four candidate loci, which were mapped to chr6, chr7, chr12 and chr13. The present study aimed to identify the locus involved functionally in NAFLD around the association signal observed in chr13.

2022-08-25 | GSE211832 | GEO

Global Soil Mycobiome Consortium II dataset

Project description:Global Soil Mycobiome Consortium II dataset Targeted loci

| PRJNA1091046 | ENA